Sensory ganglia require neurotrophin-3 early in development

Development ◽  
1994 ◽  
Vol 120 (6) ◽  
pp. 1613-1619 ◽  
Author(s):  
F. Gaese ◽  
R. Kolbeck ◽  
Y.A. Barde
Keyword(s):  
Monoclonal Antibody ◽  
Biological Activity ◽  
Dorsal Root ◽  
Essential Role ◽  
Neuronal Cell ◽  
Sensory Ganglia ◽  
Antibody Treatment ◽  
Ganglion Nodosum ◽  
Cell Counts ◽  
Neurotrophin 3

The role played by neurotrophin-3 during the development of quail sensory ganglia was investigated using a monoclonal antibody that specifically blocks the biological activity of this neurotrophin. Neutralisation of neurotrophin-3 was initiated during completion of gangliogenesis. Neuronal cell counts indicate that about 30% of the neurons normally present in either the placode-derived ganglion nodosum or in a leg-innervating, neural crest-derived dorsal root ganglion are eliminated by the antibody treatment. In both ganglia, this reduction is seen early in development, and the results obtained with the ganglion nodosum indicate that neurotrophin-3 plays an essential role already during gangliogenesis. Neuronal numbers are also compared with those obtained after treatment with a monoclonal antibody to nerve growth factor, used either alone or in combination with the neurotrophin-3 antibody.

scholarly journals Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 990
Author(s):  
Herman Morchel ◽  
David Clark ◽  
Leighanne Buenvenida ◽  
Chinwe Ogedegbe
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
Patient Care ◽  
Emergency Care ◽  
Environmental Changes ◽  
Physical Space ◽  
Antibody Treatment ◽  
Monoclonal Antibody Treatment ◽  
Mobile Satellite ◽  
Novel Coronavirus

The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance entrance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

Sign in / Sign up

Export Citation Format

Share Document